经动脉灌注化疗或栓塞治疗恶性胰岛素瘤肝转移

目的 探讨经动脉灌注化疗或栓塞治疗恶性胰岛素瘤肝转移的临床效果.方法 对9例恶性胰岛素瘤肝转移患者,采用5-FU、表阿霉素、丝裂霉素C和IL-2的化疗方案进行经导管动脉灌注化疗,2例患者还接受了肝动脉化疗栓塞,共2～8个疗程.结果 所有患者均顺利完成介入治疗,无严重并发症.治疗后临床症状消失或明显改善,显效2例、有效7例;影像学疗效评价显效1例、有效7例、无效1例.结论 经动脉灌注化疗或栓塞治疗恶性胰岛素瘤肝转移安全有效.     

经保留导管区域性动脉灌注化疗胰腺癌的疗效观察

目的　探讨经保留导管区域性动脉灌注化疗胰腺癌的疗效及价值。方法　本文15例胰腺癌患者,采用Seldinger技术经股动脉穿刺插管后,将导管先端插进腹腔动脉干,然后把导管的体外段盘曲、固定在腹股沟韧带上方。术毕采用ADF方案经保留导管行腹腔动脉干区域性灌注化疗。结果　本文15例胰腺患者中,黄疸完全消退者8例,减轻者4例,总有效率80%（12/15）;腹痛症状消失者9例,减轻者6例。食欲改善及体重有增加者共12例。生存期1,2,3年分别为9例、5例和3例。结论　本文结果表明,对胰腺癌的治疗,区域性动脉灌注化疗明显优于全身静脉化疗。     

肿瘤动脉灌注化疗和栓塞治疗的护理

我院自1990年4月～1991年2月应用经动脉插管化疗和栓塞治疗各种肿瘤33例,其中男29例,女4例;年龄28～69岁;原发性肝癌19例,贲门癌5例,肺癌3例,胃癌2例,直结肠癌伴肝转移3例,胰腺癌伴肝转移1例;共灌注39次。近期疗效满意,未发生严重并发症,现将护理中的几点体会总结如下: 1 术前心理护理动脉灌注化疗和栓塞治疗肿瘤,是创伤性治疗,术前做好心理护理,争取患者及其亲属配合十分重     

贲门癌肝转移的血供特点及其与经动脉化疗栓塞疗效的相关性

目的探讨贲门癌肝转移的血供特点及其与经动脉化疗栓塞治疗效果的关系。方法对42例经临床和病理组织学证实的贲门癌肝转移患者同时行贲门及肝脏肿瘤靶动脉栓塞化疗术。随后,在所有患者中观察了病灶血供特点,并评价了经动脉化疗栓塞治疗的效果及生存率。结果贲门癌病灶主要由胃左动脉供血,左膈下动脉、胃右动脉及肝左动脉可能参与供血。肝转移瘤由肝动脉供血,其中富血供、染色征明显者6例(14.3%),治疗有效率为83.3%;血供中等、染色较淡28例(66.7%),治疗有效率为53.5%;血供稀少、染色呈淡絮状或无明显染色8例(19.0%),治疗有效率为37.5%。经动脉化疗栓塞术后,0.5、1、2、3、5a生存率分别为90.4%,76.1%,33.3%,7.1%和2.4%。本组患者于诊断后中位生存期为19.6个月。结论经动脉化疗栓塞治疗是贲门癌肝转移的有效治疗方法,富血供肿瘤疗效优于乏血供肿瘤。     

选择性肝动脉化疗药物灌注及栓塞治疗肝转移癌

目的 探讨选择性肝动脉化疗药物灌注及栓塞治疗肝转移癌的价值。材料与方法对122例失去手术机会的肝转移癌患者，采用经股动脉穿刺，选择性肝动脉插管灌注化疗药物(ADM，MMC，CDDP，5-FU)，并用ADM及碘化油乳化后检塞肝动脉。结果近期疗效以CT检查结果作为评价标准，总有效率为54％(66／122)，平均生存期22．2个月。0．5、1、2、3年生存率分别是98．3％、80．4％、40．9％、10．6％。结论经肝动脉化疗药物灌注及栓塞治疗是失去手术机会的肝转移癌患者的一种安全、有效的姑息性治疗方法，其不仅能提高疗效，而且能改善患者的生活质量。     

肝动脉化疗或栓塞治疗胰腺神经内分泌肿瘤肝转移的疗效分析

目的 评价经肝动脉灌注化疗或栓塞治疗胰腺神经内分泌肿瘤肝转移的临床效果.方法 对21例胰腺神经内分泌肿瘤肝转移患者,共进行77例次经动脉介入治疗,其中单纯经动脉灌注化疗54例次,肝动脉化疗栓塞23例次.分析临床疗效、影像学评价、无进展生存期(PFS)、总生存期(OS)和并发症.结果 所有患者均顺利完成介入治疗,无严重并发症发生.临床反应为显效10例、有效6例、无效5例,总有效率76.2%(16/21);影像学疗效评价有效11例、稳定4例、疾病进展6例;PFS(15.0 ± 10.9)个月,OS(31.2 ± 17.4)个月.结论 经肝动脉灌注化疗或栓塞治疗胰腺神经内分泌肿瘤肝转移安全有效,可作为不能手术切除患者的一线治疗方法.     

选择性动脉化疗药物灌注及栓塞治疗结肠直肠癌肝转移

目的：探讨选择性动脉２化疗药物灌注及栓塞治疗结直肠癌肝转移的价值。材料与方法：对２７例失去手术机会的结直肠癌肝转移患者,采用经股动脉穿刺,选择性肝动脉插管灌注化疗药物（ＡＤＭ,ＣＢＰ,ＦＵＤＲ）,并用ＡＤＭ及磺化油乳化后栓塞肝动脉。结果：在第１疗程结束后,１９例患者肝内肿瘤有缩小,２５例ＣＥＡ降低,２３例上腹疼痛减轻或消失。１、２、３年生存率辊７０．４％、５１．９％、２２．２％。结论：经肝动脉化疗     

结直肠癌肝转移动脉化疗栓塞与全身静脉化疗的疗效对比分析

目的 通过比较经肝动脉灌注化疗栓塞与全身静脉化疗治疗结直肠癌肝转移的疗效及生存率,旨在为临床制定合理治疗方案提供依据.资料与方法 回顾性分析45例临床分期相同但治疗方法不同的结直肠癌患者资料,将其分为肝动脉化疗栓塞组及全身静脉化疗组.其中肝动脉灌注化疗栓塞治疗组27例,全身静脉化疗组18例.两组均采用Folfox方案化疗,治疗前后行血常规、肝肾功能及肝脏增强CT检查.随访其生存结果,分析两组的完全缓解(CR)、部分缓解(PR)及1、2、3年生存率.结果 肝动脉化疗栓塞组的CR、PR率(20%、35%)显著高于静脉化疗组(6.25%、25%)(P<0.05);肝动脉灌注化疗组的中位生存期为(25± 0.5)个月,明显高于全身静脉化疗组生存期(13±0.5)个月;肝动脉灌注化疗组的1、2、3年生存率(62.96%、48.14%、22.2%)也显著高于静脉化疗组(38.89%、16.67%、0%)(P<0.05).结论 肝动脉灌注化疗栓塞治疗结肠癌肝转移优于全身静脉化疗.     

胃及大肠癌术后区域性动脉灌注化疗和腹腔泵温热灌注化疗的临床应用

目的探索胃及大肠癌术后的治疗、预防复发和转移的方法。方法对50例术后1～12个月胃及大肠癌患者依据化疗方法的不同分为两组:治疗组24例采取区域性动脉灌注化疗联合腹腔泵温热灌注化疗;对照组26例采取术后区域性动脉灌注化疗。跟踪随访12～36个月。结果治疗组生存率提高、术后肝转移率及腹腔内种植率均低于对照组,两者差异有显著性,P值<0.05。结论区域性动脉灌注化疗联合腹腔泵温热灌注化疗疗效明确,安全性高,能有效降低胃及大肠癌术后复发及腹腔内转移,并对术前已有腹腔内转移者能抑制肿瘤生长速度,延长患者生存期。     

脂肪乳作为溶剂行胰腺区域性动脉灌注化疗的临床应用

目的 探讨以脂防乳作为溶剂,行胰腺癌区域性动脉灌注化疗治疗中晚期胰腺癌的疗效.方法 6例中晚期胰腺癌选择性动脉插管于胰腺癌的供血动脉,灌注吉西他滨、20%脂肪乳混合液.观察疗效、临床受益反应、患者的生存期及不良反应等.结果 6例均获临床受益,2例均获临床缓解,Kaplan-Meier法计算6、9和12个月的分别生存6例、5例和4例.结论 以脂肪乳作为溶剂.行胰腺癌区域性动脉灌注化疗治疗中晚期胰腺癌.可获得较好的临床疗效,患者耐受良好,值得进一步研究.     

Feeding Artery of Laryngeal and Hypopharyngeal Cancers: Role of the Superior Thyroid Artery in Superselective Intraarterial Chemotherapy

The purpose of this study was to elucidate the role of the superior thyroid artery in intra-arterial infusion chemotherapy for laryngeal and hypopharyngeal cancers. Thirty-nine patients with laryngeal cancer and 29 patients with hypopharyngeal cancer underwent intra-arterial infusion chemotherapy. We performed a retrospective analysis of the feeding arteries confirmed by computed tomography during selective arteriography and compared the results with the extent of the tumors. In 14 of 39 laryngeal and 15 of 29 hypopharyngeal cancers, the tumor did not cross the midline (group 1). In the remaining 25 and 14 cancers, respectively, the tumor crossed the midline or located in the center (group 2). For 13 of 14 laryngeal and 7 of 15 hypopharyngeal cancers in group 1 and for 6 of 25 laryngeal cancers in group 2, the entire tumor was contrast enhanced by the ipsilateral superior thyroid and/or superior laryngeal artery. For 12 of 25 laryngeal and 1 of 14 hypopharyngeal cancers in group 2, the entire tumor was contrast enhanced by the bilateral superior thyroid artery. For the other patients, infusion via the other arterial branches such as the inferior thyroid and the lingual arteries were needed to achieve contrast enhancement of the entire tumor. Superselective intra-arterial chemotherapy for laryngeal cancer from the superior thyroid artery is appropriate, whereas that for hypopharyngeal cancer is less sufficient. To accomplish contrast enhancement of the entire tumor, additional intra-arterial infusion from other arteries such as the inferior thyroid artery is often necessary.     

经淋巴管免疫化疗治疗淋巴转移癌

目的:在研究经淋巴管内灌注抗癌药物和细胞因子等生物制剂治疗恶性肿瘤的效果。材料与方法:23例晚期转移性癌肿和2例原发性恶性淋巴瘤,对常规化疗或经动脉内化疗无效,而采用淋巴管内灌注治疗。结果:淋巴管造影注药.1月后复查淋巴结摄片和 CT 扫描进行对比,发现23例经免疫化疗的肿大淋巴结均有缩小。结论:经淋巴管灌注疗法对淋巴道路转移痛和恶性淋巴瘤是安全、有效的方法,并无严重并发症。     

晚期胰腺癌合并梗阻的三介入治疗

目的 :探讨晚期胰腺癌合并阻塞性黄疸及十二指肠梗阻的介入治疗方法 ,对供血动脉药物灌注及胆道支架、十二指肠支架植入的临床效果予以讨论。方法 :采用seldinger技术经股动脉插管胰腺供血动脉灌注化疗药物 ,经皮经肝穿刺植入胆道支架 ,经口经胃植入十二指肠支架。结果 :6例病人疼痛症状明显缓解 ,黄疸及十二指肠梗阻解除。结论 :动脉灌注化疗药物对降低肿瘤生长速度和减轻疼痛是一种可选择的有效方法 ,但对减小肿瘤体积、改善黄疸及十二指肠梗阻疗效轻微 ,经皮经肝植入胆道支架、经口经胃植入十二指肠支架可有效解除黄疸及十二指肠梗阻 ,改善症状、延长病人生存期。     

Intra-arterial Infusion Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Preliminary Experience on the Safety,Efficacy, and Clinical Outcomes

PurposeTo investigate the effectiveness and toxicity of intra-arterial infusion chemotherapy as a therapeutic modality for advanced non–small-cell lung cancer (NSCLC).Materials and MethodsIn a retrospective study, 40 patients with stage III NSCLC received intra-arterial infusion chemotherapy with gemcitabine and cisplatin. Tumor staining was graded based on angiography, and the number of NSCLC feeding arteries detected was recorded. Toxicity was assessed according to National Cancer Institute Common Toxicity Criteria for Adverse Events. The response to treatment was evaluated per Response Evaluation Criteria In Solid Tumors (RECIST). Efficacy was assessed based on time to tumor progression (TTP), and survival was estimated by Kaplan–Meier analysis. Prognostic factors influencing TTP and overall survival rate were evaluated by Cox regression analysis.ResultsThe most frequent drug-related adverse events were cough (n = 17; 42.5%), anorexia (n = 14; 35%), and pain (n = 9; 22.5%). Evaluated per RECIST, a total of 47.5% of patients (n = 19) exhibited response to therapy after completion of the first three cycles of intra-arterial infusion chemotherapy. The median TTP was 5 months. Patients had a median life expectancy of 9 months. By Cox regression analysis, tumor staining was shown to be an independent prognostic factor for TTP (relative risk, 0.405; 95% confidence interval, 0.216–0.760) and overall survival (relative risk, 0.348; 95% confidence interval, 0.185–0.656).ConclusionsIntra-arterial infusion chemotherapy for advanced lung cancer has the potential to reduce the size of tumors and has no severe adverse effects.     

不可手术切除的肝细胞癌的疗效评价标准——改良RECIST标准更可靠

目前,临床上对于不可手术切除的肝细胞癌的治疗多采用介入疗法,近几年兴起的分子靶向药物索拉非尼在治疗中也占有一席之地.介入治疗和分子靶向药物治疗的作用机制均为导致肿瘤坏死,但病灶总体积往往保持不变甚至增大,采用传统的实体瘤的疗效评估标准(response evaluation criteria in solid tumor,RECIST)已不能满足准确、全面评估其疗效的需求,常出现低估疗效或假阳性进展的结果.改良RECIST标准以"存活肿瘤"对靶病灶进行疗效评价,能更准确、全面地评价肿瘤内部的变化.对于介入治疗和靶向药物等治疗,改良RECIST标准的评估结果更可靠.     

Brain infarction after percutaneous implantation of port-catheter system via the left subclavian artery

The aim of this study was to evaluate the incidence of brain infarction after percutaneous implantation of a port-catheter system via the left subclavian artery for hepatic arterial infusion chemotherapy. In 90 patients with inoperable liver cancer, a port-catheter system was implanted via the left subclavian artery. In 5 patients (5.6%) brain infarction occurred after port-catheter implantation. In one patient (1.1%) thrombi formed around the catheter, as confirmed by autopsy. The risk of brain infarction should be taken into consideration when a trans-left subclavian arterial access route is used for the percutaneous implantation of a port-catheter system for hepatic arterial infusion chemotherapy.     

胸廓内动脉的血管解剖及其在介入治疗中的价值

目的:探讨胸廓内动脉的血管解剖及其在介入治疗中的价值。方法:在22例肝癌及胸部疾患的介入治疗中运用了经胸廓内动脉插管DSA造影,对胸廓内动脉参与病变供血的病例进行了介入治疗,并进行了经验总结。结果:胸廓内动脉参与病变供血12例,胸廓内动脉行程长、分支及供血器官较多,对胸廓内动脉参与供血的病变进行介入治疗有重要价值。结论:胸廓内动脉在肝癌及胸部疾患的介入治疗中不应忽视。     

经动脉介入栓塞治疗胰头癌临床观察(附13例报告)

目的 探讨介入动脉栓塞治疗中晚期胰头癌的疗效.方法对13例胰头癌患者进行胰十二指肠动脉造影后,超选入肿瘤供血动脉灌注健择1000 mg,然后用健择200 mg和10 ml碘化油混悬液进行栓塞,4周后行CT扫描评价疗效.结果所有患者临床症状明显减轻,肿块明显缩小.结论 动脉栓塞治疗胰头癌有较好的疗效,是目前临床治疗胰头癌的可行有效方法之一.     

介入诊疗中提倡使用等渗性对比剂

影像诊断和介入治疗技术的快速发展使对比剂的临床应用越来越普遍,与对比剂相关的不良事件亦日益受到医学界的重视.对比剂肾病是临床最常见的对比剂相关不良事件,对比剂的神经毒性反应也开始受到临床医师的关注.等渗性对比剂的渗透压接近血浆,其安全性和耐受性较低渗性对比剂更好.因此,在临床工作中应提倡使用等渗对比剂,这对减少对比剂不良事件具有重要意义.